/ The Lancet Neurology

Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial

Engelter ST, Traenka C, Gensicke H, Schaedelin SA, Luft AR, Goeggel Simonetti B, Fischer U, Michel P, Sirimarco G, Kägi G, Vehoff J, Nedeltchev K, Kahles T, Kellert L, Rosenbaum S, von Rennenberg R, Sztajzel R, Leib SL, Jung S, Gralla J, Bruni N, Seiffge D, Feil K, Polymeris AA, Steiner L, Hamann J, Bonati LH, Brehm A, De Marchis GM, Peters N, Stippich C, Nolte CH, Christensen H, Wegener S, Psychogios MN, Arnold M, Lyrer P, on behalf of the TREAT-CAD investigators

The Lancet Neurology
March 22, 2021 https://doi.org/10.1016/S1474-4422(21)00044-2

TREAT-CAD is a multicenter, controlled-randomized therapy study that investigated whether ruptures in the wall of brain-supplying arteries - dissections - can be treated with aspirin, or whether more complex blood thinning (anticoagulation) is necessary. An international group of researchers from 10 centers - 7 in Switzerland, 2 in Germany, 1 in Denmark - led by DKF research group leader Prof. Dr. Stefan Engelter (University Geriatric Medicine FELIX Platter, University of Basel and University Hospital Basel, Stroke Center) supported by Dr. Christopher Traenka (UAFP, USB-SC), Prof. Dr. Philippe Lyrer (USB-SC) have been able to show that aspirin is not as effective as anticoagulation.

From Basel, PD Dr Henrik Gensicke (UAFP, USB-SC), Sabine Schaedelin (DKF), Dr Nicole Bruni (DKF), PD Dr David Seiffge (USB USB-SC, Inselspital Bern), Dr. Alexandros Polymeris (USB-SC, UAFP), Prof Dr. Leo Bonati (USB-SC), Dr. Alex Brehm (USB-SC), PD Dr. Gian Marco De Marchis (USB-SC), Professor Dr. Nils Peters (UAFP, USB, Hirslanden Zurich) and Prof. Dr. Marios Psychogios (USB-SC) actively contributed to the success of the study.